A head-to-head comparison in the European Journal context reports that FAPI-04 PET/CT outperformed FDG in detecting recurrent breast cancer after surgery. The tracer targets fibrous tumor-associated structures rather than glucose metabolism, aiming to improve specificity for residual or recurrence detection when FDG signal may be ambiguous. The clinical question—finding recurrence early and accurately—directly impacts downstream decisions on imaging cadence, biopsy selection, and treatment initiation. A better-performing tracer can also change the economics of follow-up imaging by reducing false positives and additional workups. For imaging developers and nuclear medicine teams, the result supports continued diversification of PET targets beyond glucose, especially in postoperative settings where interpretability is challenging.